{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:54:10Z","timestamp":1780725250225,"version":"3.54.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>As the safety and availability of allogeneic hematopoietic stem cell transplantation (HSCT) have improved, this procedure is becoming a viable option for nonmalignant conditions such as sickle cell disease (SCD). There are very few treatment options available for SCD, and even with optimal care SCD patients still suffer from a myriad of comorbidities to multiple organ systems and have a decreased life span. In this review, we will summarize results from trials of HSCT for children or adults with SCD using a variety of graft sources as well as conditioning and graft-versus-host disease prophylaxis regimens, and discuss the unique challenges that arise in these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>AlloHSCT for SCD has been performed on small numbers of patients at multiple centers around the world using several different transplant platforms, and early outcomes are encouraging. Overall survival is excellent, although graft failure remains a challenge.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>As alloHSCT becomes safer and more widely available, the procedure should be considered for patients with severe disease phenotypes in whom the potential benefits of transplantation outweigh the complications from the disease. AlloHSCT has been shown to reverse or at least halt the progression of end-organ damage secondary to SCD. More research is needed to understand the mechanisms underlying graft failure in SCD recipients, as well as to understand the biopsychosocial underpinnings of persistent pain in the posttransplant period to maximize the benefit from the transplant procedure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/moh.0000000000000282","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T17:06:24Z","timestamp":1470762384000},"page":"524-529","source":"Crossref","is-referenced-by-count":28,"title":["Allogeneic stem cell transplantation for sickle cell disease"],"prefix":"10.1097","volume":"23","author":[{"given":"Tara M.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"issue":"(Suppl)","key":"R2-20230917","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/bmt.2015.93","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update","volume":"50","author":"Bacigalupo","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.bbmt.2014.03.009","article-title":"Peripheral blood stem cells for T cell-replete nonmyeloablative hematopoietic transplants using posttransplant cyclophosphamide","volume":"20","author":"Bashey","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"E284","DOI":"10.1002\/ajh.24340","article-title":"Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older","volume":"91","author":"Konuma","year":"2016","journal-title":"Am J Hematol"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bbmt.2010.07.022","article-title":"One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing","volume":"17","author":"Valc\u00e1rcel","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the US","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: US","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/j.amepre.2011.09.006","article-title":"Disability among individuals with sickle cell disease: literature review from a public health perspective","volume":"41","author":"Swanson","year":"2011","journal-title":"Am J Prev Med"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-marrow transplantation in a patient with sickle-cell anemia","volume":"311","author":"Johnson","year":"1984","journal-title":"N Engl J Med"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM199608083350601","article-title":"Bone marrow transplantation for sickle cell disease","volume":"335","author":"Walters","year":"1996","journal-title":"N Engl J Med"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2141.2007.06592.x","article-title":"Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research","volume":"137","author":"Panepinto","year":"2007","journal-title":"Br J Haematol"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.12737","article-title":"Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients","volume":"165","author":"Dedeken","year":"2014","journal-title":"Br J Haematol"},{"key":"R14-20230917","article-title":"Bone marrow transplant in patients with sickle cell anaemia. Experience in one centre","author":"Garc\u00eda Morin","year":"2016","journal-title":"An Pediatr (Barc)"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bbmt.2013.02.010","article-title":"Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease","volume":"19","author":"Dallas","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1701291","article-title":"Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium","volume":"22","author":"Vermylen","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.bmt.1704443","article-title":"Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcome","volume":"33","author":"Brachet","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1542\/peds.2014-0571","article-title":"Immunologic effects of hydroxyurea in sickle cell anemia","volume":"134","author":"Lederman","year":"2014","journal-title":"Pediatrics"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2008.08.016","article-title":"Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease","volume":"14","author":"Krishnamurti","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.bbmt.2015.01.015","article-title":"Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial","volume":"21","author":"Horan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1083-8791(03)00192-7","article-title":"Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia","volume":"9","author":"Iannone","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2012.01.019","article-title":"Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)","volume":"18","author":"Kamani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bola\u00f1os-Meade","year":"2012","journal-title":"Blood"},{"key":"R25-20230917","first-page":"27","article-title":"Availability of related donors for bone marrow transplantation in sickle cell anemia","volume":"16","author":"Mentzer","year":"1994","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcmd.2015.03.012","article-title":"The effects of hydroxyurea and bone marrow transplant on Anti-M\u00fcllerian hormone (AMH) levels in females with sickle cell anemia","volume":"55","author":"Elchuri","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bbmt.2009.10.005","article-title":"Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease","volume":"16","author":"Walters","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R28-20230917","doi-asserted-by":"crossref","DOI":"10.1093\/humrep\/dew084","article-title":"The medical and ethical challenges of fertility preservation in teenage girls: a case series of sickle cell anaemia patients prior to bone marrow transplant","author":"Lavery","year":"2016","journal-title":"Hum Reprod"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bbmt.2014.07.020","article-title":"Calcineurin inhibitor \u2013 free graft-versus-host disease prophylaxis with posttransplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation","volume":"20","author":"Solomon","year":"2014","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Current Opinion in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00062752-201611000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T05:54:35Z","timestamp":1694930075000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00062752-201611000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/moh.0000000000000282","relation":{},"ISSN":["1065-6251","1531-7048"],"issn-type":[{"value":"1065-6251","type":"print"},{"value":"1531-7048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}